tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

IMRX Stock Latest News

Immuneering presents preclinical data on IMM-1-104 at AACR 2024
The FlyImmuneering presents preclinical data on IMM-1-104 at AACR 2024
23d ago
IMRX
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
PremiumPress Releases
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
23d ago
IMRX
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
PremiumPress Releases
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
29d ago
IMRX
Immuneering price target lowered to $8 from $20 at Mizuho
PremiumThe Fly
Immuneering price target lowered to $8 from $20 at Mizuho
1M ago
IMRX
Immuneering announces first patient dosed in Phase 1/2 trial of IMM-6-415
PremiumThe Fly
Immuneering announces first patient dosed in Phase 1/2 trial of IMM-6-415
1M ago
IMRX
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
PremiumPress ReleasesImmuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
1M ago
IMRX
Immuneering price target lowered to $15 from $20 at Needham
PremiumThe Fly
Immuneering price target lowered to $15 from $20 at Needham
2M ago
IMRX
Immuneering price target lowered to $16 from $21 at Chardan
PremiumThe Fly
Immuneering price target lowered to $16 from $21 at Chardan
2M ago
IMRX
Immuneering downgraded to Hold from Buy at Jefferies
PremiumThe Fly
Immuneering downgraded to Hold from Buy at Jefferies
2M ago
IMRX
Immuneering downgraded to Market Perform from Outperform at TD Cowen
PremiumThe Fly
Immuneering downgraded to Market Perform from Outperform at TD Cowen
2M ago
IMRX
Immuneering downgraded to Neutral from Buy at Guggenheim
PremiumThe Fly
Immuneering downgraded to Neutral from Buy at Guggenheim
2M ago
IMRX
Immuneering Corp trading resumes
PremiumThe Fly
Immuneering Corp trading resumes
2M ago
IMRX
Immuneering Corp trading halted, volatility trading pause
PremiumThe FlyImmuneering Corp trading halted, volatility trading pause
2M ago
IMRX
Immuneering Appoints New Director, Advances Cancer Drug Trial
PremiumCompany Announcements
Immuneering Appoints New Director, Advances Cancer Drug Trial
2M ago
8K
IMRX
Immuneering announces near-term milestone expectations
PremiumThe Fly
Immuneering announces near-term milestone expectations
2M ago
IMRX
Immuneering announces results from Phase 1 portion of IMM-1-104 Phase 1/2a trial
PremiumThe Fly
Immuneering announces results from Phase 1 portion of IMM-1-104 Phase 1/2a trial
2M ago
IMRX
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
PremiumPress Releases
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
2M ago
IMRX
Immuneering appoints Thomas Schall to board of directors
PremiumThe Fly
Immuneering appoints Thomas Schall to board of directors
2M ago
IMRX
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
PremiumPress Releases
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
2M ago
IMRX
Immuneering doses first patient in Phase 2a trial of IMM-1-104
PremiumThe FlyImmuneering doses first patient in Phase 2a trial of IMM-1-104
2M ago
IMRX
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
PremiumPress Releases
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
2M ago
IMRX
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
PremiumPress Releases
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
2M ago
IMRX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >